BIOGRAPHICAL SKETCH
Provide the following information for the key personnel in the order listed for Form Page 2.
Follow the sample format on for each person. (See attached sample).
DO NOT EXCEED FOUR PAGES.
NAME POSITION TITLE
Professor, Departments of Medicine & Pediatrics
Mark William Duncan, Ph.D. Director, UCCC Proteomics Shared Resource
EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.)
INSTITUTION AND LOCATION DEGREE
(if applicable)
YEAR(s) FIELD OF STUDY
UNSW, Sydney, Australia
UNSW, Sydney, Australia
Garvan Institute, Sydney Australia
NINDS, NIH
A. Positions and Honors
B.Sc. (Hons) 1979
Ph.D. 1984-1987
Organic Chemistry
Neuroscience/Anal Chem
Postdoc
Postdoc
1986-1987
1987-1990
Neuroscience/Anal Chem
Neuroscience/Neurology
Positions and Employment:
1990 Visiting Associate, NINDS, NIH
1990 – 1993 Director, Biomedical Mass Spectrom. Unit & Senior Lecturer, Faculty of Medicine, University of New South Wales (UNSW), Sydney, Australia.
1994 – 1999 Director, Biomed. Mass Spectrom. Facility & Assoc. Prof., Medicine, UNSW, Sydney, Aust.
1995 Visiting Scientist, laboratory of Dr. Bruce Ames, University of California, Berkeley (6 months).
1999 – 2004 Director , Biochemical Mass Spectrometry Facility & Professor, School of Pharmacy, UCHSC.
1999 – Current Graduate Faculty, University of Colorado Health Sciences Center.
2000 – Current Professor, Department of Biochemistry & Molecular Genetics, UCHSC.
2000 – Current Member, University of Colorado Structural Biology Program
2004 – Current Professor of Medicine, Departments of Pediatrics (Pulmonary Division) & Medicine (Division of Endocrinology, Diabetes & Metabolism) UCHSC
2004 – Current Director, UC Cancer Center Proteomics Shared Resource
2005 – Current Professor, Department of Cellular & Developmental Biology
Other Experience, Honors and Professional Memberships:
1984 – 1987 National Health & Medical Research Council of Australia, Biomedical Post-Graduate Scholar.
1985 Foundation Research & Treatment of Alcoholism & Drug Dependence Prize (NSW, Australia)
1987 – 1990 Fogarty Visiting Fellowship, National Institutes of Health (Drs. I.J. Kopin and S.P. Markey).
1995 Convener, 43rd Australian & N.Z. Soc. for Mass Spectrom. Conference, Sydney, Australia
1996 & 2001 Faculty, NATO Training School, Biological Mass Spectrometry (Italy and Morocco)
1997 – 2003 Am. Soc. Mass Spectrom. Instructor, Short Course on Quantitative Mass Spectrometry
2000 – 2004 Member, Scientific Board of Directors, M.I.N.D. Institute, UC Davis
2000 – 2004 Member, Measurements and Standards Committee, American Society for Mass Spectrometry
2002 – 2007 Editorial Board, Journal of Protein Chemistry
2004 – Current Committee Member, National Committee for Clinical Laboratory Standards (NCCLS), Mass
Spectrometry in the Clinical Laboratory
2006- Associate Editor, Journal of Experimental Biology and Medicine (Genomics, Proteomics, and
Bioinformatics Section)
2006-
2006-
Member, Education Board, Practical Proteomics, Proteomics.
Standards & Poor, Society of Industry Leaders (SIL)
Study Section Participation (Last 5 years)
NIA site visit (2000); NIH Shared Instrumentation Grants Committee (2001, 2003); Ad hoc NHLBI study section
(2002); Ad hoc NIAAA study section (2002); site visit, Lawrence Livermore (2004); permanent member, Mol. and Cell. Endocrinology (MCE) Study Section (2004-); member, Special Review Panel, The Early Detection
Research Network: Biomarker Developmental Laboratories, NCI, NIH (2004), NIEHS Proteomics Study
Section (2005), SBIR Study Section (2005, 2006) NIA Program/Project Study Section (2005).

B. Selected peer-reviewed publications in chronological order (selected):

Duncan MW, Compton P, Lazarus L, Smythe GA. Measurement of norepinephrine and 3,4dihydroxyphenylglycol in urine and plasma for the diagnosis of pheochromocytoma. N Engl J Med.
1988:319(3);136-42.

Duncan MW, Kopin IJ, Garruto RM, Lavine L, Markey SP. 2-Amino-3 (methylamino)-propionic acid in cycad-derived foods is an unlikely cause of amyotrophic lateral sclerosis/parkinsonism [letter]. Lancet.
1988:2(8611);631-2.

Duncan MW, Steele JC, Kopin IJ, Markey SP. 2-Amino-3-(methylamino)-propanoic acid (BMAA) in cycad flour: an unlikely cause of amyotrophic lateral sclerosis and parkinsonism-dementia of Guam. Neurology.
1990:40(5);767-72.

Gieseg SP, Simpson JA, Charlton TS, Duncan MW, Dean RT. Protein-bound 3,4-dihydroxyphenylalanine is a major reductant formed during hydroxyl radical damage to proteins. Biochemistry.
1993:32(18);4780-6.

Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R,
Williams KL, Humphery-Smith I. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium . Electrophoresis. 1995:16(7);1090-4.

Domigan NM, Charlton TS, Duncan MW, Winterbourn CC, Kettle AJ. Chlorination of tyrosyl residues in peptides by myeloperoxidase and human neutrophils. J Biol Chem.
1995:270(28);16542-8.

Cordwell SJ, Wilkins MR, Cerpa-Poljak A, Gooley AA, Duncan MW, Williams KL, Humphery-Smith I. Crossspecies identification of proteins separated by two-dimensional gel electrophoresis using MALDI-TOF mass spectrometry and amino acid composition. Electrophoresis.
1995:16;438-443.

Christen S, Woodall A, Shigenaga M, Southwell-Keely P, Duncan MW, Ames BN. g-tocopherol traps mutagenic electrophiles such as NO
(X)
and complements a-tocopherol: physiological implications. Proc Natl
Acad Sci U S A.
1997:94;3217-22.

Davies SM, Poljak A, Duncan MW, Smythe GA, Murphy MP. Measurements of protein carbonyls, ortho - and meta -tyrosine and oxidative phosphorylation complex activity in mitochondria from young and old rats.
Free Radic Biol Med.
2001:31(2);181-90. Erratum: 31(4):559.

Wolthers T, Hoffman DM, Nugent AG, Duncan MW, Umpleby M, Ho KK. Oral estrogen antagonizes the metabolic actions of growth hormone in growth hormone-deficient women. Am J Physiol Endocrinol
Metab.
2001:81(6);E1191-6.

Naranda T, Kaufman RI, Li J, Wong K, Boge A, Hallen D, Fung KY, Duncan MW, Andersen N, Goldstein A,
Olsson L. Activation of erythropoietin receptor through a novel extracellular binding site. Endocrinology.
2002:143(6);2293-302.

Fessler MB, Malcolm KC, Duncan MW, Worthen GS. A genomic and proteomic analysis of activation of the human neutrophil by lipopolysaccharide and its mediation by p38 mitogen-activated protein kinase . J
Biol Chem.
2002:277(35);31291-302.

Bucknall M, Fung K, Duncan MW. Practical quantitative applications of MALDI-TOF mass spectrometry . J
Am Soc Mass Spectrom.
2002:13(9);1015-27

Fung K, Morris C, Duncan M. Mass spectrometric techniques applied to the analysis of human tears: a focus on the peptide and protein constituents. Adv Exp Med Biol.
2002:506(Pt A):601-5.

Nicolls MR, D'Antonio JM, Hutton JC, Gill RG, Czwornog JL, Duncan MW. Proteomics as a tool for discovery: Proteins implicated in Alzheimer's disease are highly expressed in normal pancreatic islets. J
Proteome Res.
2003:2(2);199-205

Peebles K, Duncan MW, Ruch RJ, Malkinson A. Proteomic analysis of a neoplastic mouse lung epithelial cell line whose tumorigenicity is abrogated by transfection with the gap junction structural gene for connexin 43, Gja1. Carcinogenesis. 2003:24(4);651-7.

Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay. Cancer Chemother Pharmacol.
2003:52(2);159-66.

Duncan MW. Approaches to the analysis of 3-nitrotyrosine. Amino Acids. 2003:25(3-4);351-61.

Poljak A, Dawes IW, Ingelse BA, Duncan MW, Smythe GA, Grant CM. Oxidative damage to proteins in yeast cells exposed to adaptive levels of H(2)O(2). Redox Rep.
2003:8(6);371-7.


Helmke SM, Yen C-Y, Cios KJ, Nunley K, Bristow MR, Duncan MW, Perryman MB. Simultaneous a- and b-myosin heavy chain proteins by MALDI-TOF mass spectrometry. Anal Chem.
2004:76(6);1683-9.

Hammack BN, Fung KYC, Hunsucker SW, Duncan MW, Burgoon MP, Owens GP, Gilden DH. Proteomic analysis of multiple sclerosis cerebrospinal fluid. Multiple Sclerosis . 2004:10(3);245-260.

Bowler RP, Duda B, Chan ED, Enghild JJ, Ware LB, Matthay MA, Duncan MW. A Proteomic Analysis of
Pulmonary Edema Fluid & Plasma in Patients With Acute Lung Injury. Am J Physiol (Lung Cell Mol
Physiol).
2004:286(6);L1095-104.

Fung KY, Glode LM, Green S, Duncan MW. A comprehensive characterization of the peptide and protein constituents of human seminal fluid. Prostate.
2004:61(2);171-81.

Fung KYC, Morris C, Sathe S, Sack R, Duncan MW. Characterization of the in vivo forms of lacrimal specific proline-rich proteins in human tear fluid. Proteomics. 2004:4(12);3953-9.

Fung KYC, Askovic S, Basile F, Duncan MW. A simple and inexpensive approach to interfacing HPLC and
MALDI-TOF mass spectrometry. Proteomics.
2004:4(10);3121-7.

Yen CY, Helmke SM, Cios KJ, Perryman MB, Duncan MW. Quantitative analysis of proteomics using data mining. An automated system for constructing assays quickly and precisely. IEEE Eng Med Biol Mag.
2005:24(3);67-72.

Blake CA, Brown LM, Duncan MW, Hunsucker SW, Helmke SM. Estrogen Regulation of the Rat Anterior
Pituitary Gland Proteome. Exp Biol Med. 2005:230(11):800-807.

Duncan MW, Hunsucker SW. Proteomics as a Tool for Clinically Relevant Biomarker Discovery and
Validation. Exp Biol Med. 2005, 230(11):808-17.

Duncan MW, Gale PJ, Yergey AL. Quantification. In The Encyclopedia of Mass Spectrometry. Vol. 3.
Biological Applications . Part B. Elsevier. Eds. R. Caprioli & M. Gross. 2006:3:341-347.

Hunsucker SW, Duncan MW. Is protein overlap in two-dimensional gels a serious practical problem?
Proteomics.
2006:6(5):1374-1375.

Duncan, MW, Gale, JP, Yergey AL. The Principles of Quantitative Mass Spectrometry . Rockpool
Productions, 2006, 142 pages. ISBN 0-9786058-0-2

Brown LM, Helmke SM, Hunsucker SW, Netea-Maier RT, Chiang SA, Heinz DE, Shroyer KR, Duncan MW,
Haugen BR. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinogen . 2006 Jun 20; [Epub ahead of print]

Duncan MW , Solomon B. Proteomics of seminal fluid. In “ Proteomics of Human Body Fluids:
Principles, Methods and Applications ” Ed. Visith Thongboonkerd, Humana Press (2006) In press.

Duncan MW, Hunsucker SW. Comments on standards in proteomics and the concept of fitness-forpurpose. Proteomics . 2006. In press

Duncan MW, Helmk SM. Measurement of the NO metabolites, nitrite and nitrate, in human biological fluids by GC-MS. J Chromatogr B 2006. In press
C. Research Support
ACTIVE
5 P30 CA046934-17 (Paul Bunn
NIH/NCI
– PI) 03/01/88 –07/31/06
$12,141,528
Cancer Center Core Grant
Mark Duncan – Director, Protein Microchemistry Core
These funds support, in part, the operation of a UCCC Proteomics Core Resource.
2 P30 HD004024-35 (Linda Crnic - PI) 08/01/88 –06/30/08
NIH/NICHD $3,709,360
Mark Duncan – Co-Director, Mass Spectrometry and Proteomics Core
Mental Retardation and Development Disabilities (MRDD) Research Center
Aim: To provide MS and proteomics core support to the Mental Retardation and Developmental Disabilities
Research Center faculty.
5 R01 AI052164-03 (Stephen Dreskin - PI)
NIH/NIAID
07/01/03 –12/31/06
$500,000

Mark Duncan – Collaborator
Redefining the Major Peanut Allergens
The goals of this project are to combine functional assays with standard immunoblotting techniques & proteomics to define in molecular detail the peanut allergens quantitatively responsible for mast cell activation in patients with systemic reactions to peanuts.
Subcontracts for PI’s at Nat’l Jewish:
Grant (Michael Fessler)
American Heart Association
Mark Duncan – Collaborator
07/01/02 –06/30/07
$197,000
Modulation of Inflammation by Cholesterol and 3-Hydroxy-3 Coenzyme A Reductase Inhibitors: Role of the
Lipid Raft
Specific aims: Proteomics of the lipid raft
2 R37 GM032453-23 (Voelker)
NIH/NIGMS
Mark Duncan – Consortium subcontractor
07/01/04 – 06/30/08
$2,500,000
Phospholipid Dynamics in Membrane Assembly
Aims: Studies of protein ubiquitination and formation of docking complexes in the phosphatidylserine lipid transport pathway between the endoplasmic reticulum and Golgi apparatus.
1 R01 HL073720-01 (Scott Worthen) 09/19/03 –08/31/07
NIH/NHLBI
Mark Duncan – Co-Investigator
$2,561,838
Growth Factors and Signaling Pathways in Pulmonary Fibrosis
Aims: To map the activation state of cells in fibrotic lesions; to identify fibroblast secretory proteins regulated by TGF-beta and to assess their presence in pulmonary fibrosis. To identify novel therapeutic targets that can be tested in vitro and to develop biomarkers necessary to assess the impact and response of novel therapies on activity and progression of pulmonary fibrosis.
R01 EY011490-07 (V. Vasiliou)
NIH/NEI
Mark Duncan – Collaborator
12/01/97 –03/31/09
$225,000
Molecular Mechanism and Role of corneal Aldehyde Dehydrogenase
The goal of this project is to determine the mechanistic role of two aldehyde dehydrogenases (ALDH3A1 and
ALDH1A1) against UV-induced eye damage using transgenic knockout animals.
R01 NS051539-01A1 (Patterson, David)
NIH
Mark Duncan – Consortium subcontractor
07/25/04
–06/30/08
$770,000
Proteomics for Testing Hypotheses about Down Syndrome
Aim: The overall goal of this proposal is to assess protein expression in brain regions from Ts65Dn mice (an animal model of DS) using two dimensional gel electrophorsis/mass spectrometry (2DGE-MS).
R21 DK070203-02 (Nicolls, Mark) 09/30/04 –08/31/06
NIH
Mark Duncan – Consortium Subcontractor
$500,000
Viability Assay for Human Islet Transplantation
Aim: The sole specific aim of the R21 is to determine a panel of biomarkers that assess human islet viability for successful transplantation. This aim employs human islets transplanted into immunodeficient mice and will test the hypothesis that biomarkers in pre-transplanted islets can distinguish high grade (i.e. suitable for transplantation) from low grade islets .
PREVIOUS FUNDING
5 R01 CA096133-02 (Malkinson) 06/28/02 –05/31/05

NIH/NCI $340,245
Chemoprevention of Early Pulmonary Lesions in Mice by Anti-Inflammatory Drugs
RODMAN00V0 (Rodman)
Cystic Fibrosis Foundation
03/01/01 –02/29/04
$500,000
Effects of P. Aeruginosa on Inflammatory Gene Expression
Aim: To provide proteomics capabilities to the investigators involved in this program.
5 U19 DK061248-03 (John Hutton - PI) 09/30/01 –07/31/04
NIH/NIDDK
Mark Duncan – Collaborator
$988,732
Development and regeneration of the endocrine pancreas (Project 1)
Proteomic and genomic analysis of the development of the endocrine pancreas
Aims: This Program/Project focuses on the area of pancreatic islet development & regeneration and incorporates a gene/protein discovery program, studies in transcription regulation and cell signaling, and betacell transplantation into human subjects.
DUNCAN01U0 (Mark Duncan - PI)
Cystic Fibrosis Foundation
Protein Expression Analysis in Cystic Fibrosis
Mark Duncan – PI
03/01/02 –02/28/05
$871,604
The project involves a proteomic analysis of CF. Urine, saliva, plasma and tear fluid are being examined.
Grant 07/26/04 –12/31/05
Pfizer, Inc.
Mark Duncan – PI
$199,091
Practical Utility of Desorption Mass Spectroscopy Techniques
Aim: This work will investigate the practical utility of desorption mass spectrometry (MS) techniques
(specifically, matrix assisted laser desorption/ionization time-of-flight mass spectrometry – MALDI/TOF MS) for the quantitative analysis and discrimination of phosphorylated and non-phosphorylated protein pairs from biological matrices. The collaboration will determine the state-of-the-art limitation of quantitative MALDI/TOF
MS for protein quantitation from in vivo matrices